March 13 (Reuters) – Pfizer Inc (PFE.N) on Monday struck a $43 billion deal to acquire Seagen Inc (SGEN.O) and its targeted cancer therapies as it braces for a steep fall in COVID-19 sales and generic competition for some top-selling drugs. Seagen marks Pfizer’s largest purchase in a string of …